Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 8857 to 8864 of 8864 entries
Sorted by: Best Match Show Resources per page
Triple-combination therapy assisted with ultrasound-active gold nanoparticles and ultrasound therapy against 3D cisplatin-resistant ovarian cancer model.

Ultrasonics sonochemistry

Kip B, Tunc CU, Aydin O.
PMID: 34974392
Ultrason Sonochem. 2021 Dec 29;82:105903. doi: 10.1016/j.ultsonch.2021.105903. Epub 2021 Dec 29.

Cancer chemotherapy suffers from drug resistance and side effects of the drugs. Combination therapies have been attracted attention to overcome these limitations of traditional cancer treatments. Recently, increasing in intracellular chemotherapeutic concentration in the presence of ultrasonic waves (US)...

Cite
Kip B, Tunc CU, Aydin O. Triple-combination therapy assisted with ultrasound-active gold nanoparticles and ultrasound therapy against 3D cisplatin-resistant ovarian cancer model. Ultrason Sonochem. 2021;82:105903doi: 10.1016/j.ultsonch.2021.105903.
Kip, B., Tunc, C. U., & Aydin, O. (2021). Triple-combination therapy assisted with ultrasound-active gold nanoparticles and ultrasound therapy against 3D cisplatin-resistant ovarian cancer model. Ultrasonics sonochemistry, 82105903. https://doi.org/10.1016/j.ultsonch.2021.105903
Kip, Bilgi, et al. "Triple-combination therapy assisted with ultrasound-active gold nanoparticles and ultrasound therapy against 3D cisplatin-resistant ovarian cancer model." Ultrasonics sonochemistry vol. 82 (2021): 105903. doi: https://doi.org/10.1016/j.ultsonch.2021.105903
Kip B, Tunc CU, Aydin O. Triple-combination therapy assisted with ultrasound-active gold nanoparticles and ultrasound therapy against 3D cisplatin-resistant ovarian cancer model. Ultrason Sonochem. 2021 Dec 29;82:105903. doi: 10.1016/j.ultsonch.2021.105903. Epub 2021 Dec 29. PMID: 34974392.
Copy Download .nbib Format: NLM
Genetic Variation in MicroRNA-423 Promotes Proliferation, Migration, Invasion, and Chemoresistance in Breast Cancer Cells.

International journal of molecular sciences

Morales-Pison S, Jara L, Carrasco V, Gutiérrez-Vera C, Reyes JM, Gonzalez-Hormazabal P, Carreño LJ, Tapia JC, Contreras HR.
PMID: 35008806
Int J Mol Sci. 2021 Dec 29;23(1). doi: 10.3390/ijms23010380.

MicroRNA-423 (miR-423) is highly expressed in breast cancer (BC). Previously, our group showed that the SNP rs6505162:C>A located in the pre-miR-423 was significantly associated with increased familial BC risk in patients with a strong family history of BC. Therefore,...

Cite
Morales-Pison S, Jara L, Carrasco V, et al. Genetic Variation in MicroRNA-423 Promotes Proliferation, Migration, Invasion, and Chemoresistance in Breast Cancer Cells. Int J Mol Sci. 2021;23(1)doi: 10.3390/ijms23010380.
Morales-Pison, S., Jara, L., Carrasco, V., Gutiérrez-Vera, C., Reyes, J. M., Gonzalez-Hormazabal, P., Carreño, L. J., Tapia, J. C., & Contreras, H. R. (2021). Genetic Variation in MicroRNA-423 Promotes Proliferation, Migration, Invasion, and Chemoresistance in Breast Cancer Cells. International journal of molecular sciences, 23(1), . https://doi.org/10.3390/ijms23010380
Morales-Pison, Sebastian, et al. "Genetic Variation in MicroRNA-423 Promotes Proliferation, Migration, Invasion, and Chemoresistance in Breast Cancer Cells." International journal of molecular sciences vol. 23,1 (2021). doi: https://doi.org/10.3390/ijms23010380
Morales-Pison S, Jara L, Carrasco V, Gutiérrez-Vera C, Reyes JM, Gonzalez-Hormazabal P, Carreño LJ, Tapia JC, Contreras HR. Genetic Variation in MicroRNA-423 Promotes Proliferation, Migration, Invasion, and Chemoresistance in Breast Cancer Cells. Int J Mol Sci. 2021 Dec 29;23(1). doi: 10.3390/ijms23010380. PMID: 35008806.
Copy Download .nbib Format: NLM
Reduced RBPMS Levels Promote Cell Proliferation and Decrease Cisplatin Sensitivity in Ovarian Cancer Cells.

International journal of molecular sciences

Rabelo-Fernández RJ, Santiago-Sánchez GS, Sharma RK, Roche-Lima A, Carrion KC, Rivera RAN, Quiñones-Díaz BI, Rajasekaran S, Siddiqui J, Miles W, Rivera YS, Valiyeva F, Vivas-Mejia PE.
PMID: 35008958
Int J Mol Sci. 2022 Jan 04;23(1). doi: 10.3390/ijms23010535.

Worldwide, the number of cancer-related deaths continues to increase due to the ability of cancer cells to become chemotherapy-resistant and metastasize. For women with ovarian cancer, a staggering 70% will become resistant to the front-line therapy, cisplatin. Although many...

Cite
Rabelo-Fernández RJ, Santiago-Sánchez GS, Sharma RK, et al. Reduced RBPMS Levels Promote Cell Proliferation and Decrease Cisplatin Sensitivity in Ovarian Cancer Cells. Int J Mol Sci. 2022;23(1)doi: 10.3390/ijms23010535.
Rabelo-Fernández, R. J., Santiago-Sánchez, G. S., Sharma, R. K., Roche-Lima, A., Carrion, K. C., Rivera, R. A. N., Quiñones-Díaz, B. I., Rajasekaran, S., Siddiqui, J., Miles, W., Rivera, Y. S., Valiyeva, F., & Vivas-Mejia, P. E. (2022). Reduced RBPMS Levels Promote Cell Proliferation and Decrease Cisplatin Sensitivity in Ovarian Cancer Cells. International journal of molecular sciences, 23(1), . https://doi.org/10.3390/ijms23010535
Rabelo-Fernández, Robert J, et al. "Reduced RBPMS Levels Promote Cell Proliferation and Decrease Cisplatin Sensitivity in Ovarian Cancer Cells." International journal of molecular sciences vol. 23,1 (2022). doi: https://doi.org/10.3390/ijms23010535
Rabelo-Fernández RJ, Santiago-Sánchez GS, Sharma RK, Roche-Lima A, Carrion KC, Rivera RAN, Quiñones-Díaz BI, Rajasekaran S, Siddiqui J, Miles W, Rivera YS, Valiyeva F, Vivas-Mejia PE. Reduced RBPMS Levels Promote Cell Proliferation and Decrease Cisplatin Sensitivity in Ovarian Cancer Cells. Int J Mol Sci. 2022 Jan 04;23(1). doi: 10.3390/ijms23010535. PMID: 35008958.
Copy Download .nbib Format: NLM
Tumor density is associated with response to endobronchial ultrasound-guided transbronchial needle injection of cisplatin.

Journal of thoracic disease

Kinsey CM, San José Estépar R, Bates JHT, Cole BF, Washko G, Jantz M, Mehta H.
PMID: 33145055
J Thorac Dis. 2020 Sep;12(9):4825-4832. doi: 10.21037/jtd-20-674.

BACKGROUND: Endobronchial ultrasound-guided transbronchial needle injection of cisplatin (EBUS-TBNI cisplatin) is a therapeutic option for patients with recurrent lung cancer. However, the tumor characteristics that influence the distribution of the agent following intratumoral delivery remain largely unknown.METHODS: We performed...

Cite
Kinsey CM, San José Estépar R, Bates JHT, et al. Tumor density is associated with response to endobronchial ultrasound-guided transbronchial needle injection of cisplatin. J Thorac Dis. 2020;12(9):4825-4832doi: 10.21037/jtd-20-674.
Kinsey, C. M., San José Estépar, R., Bates, J. H. T., Cole, B. F., Washko, G., Jantz, M., & Mehta, H. (2020). Tumor density is associated with response to endobronchial ultrasound-guided transbronchial needle injection of cisplatin. Journal of thoracic disease, 12(9), 4825-4832. https://doi.org/10.21037/jtd-20-674
Kinsey, C Matthew, et al. "Tumor density is associated with response to endobronchial ultrasound-guided transbronchial needle injection of cisplatin." Journal of thoracic disease vol. 12,9 (2020): 4825-4832. doi: https://doi.org/10.21037/jtd-20-674
Kinsey CM, San José Estépar R, Bates JHT, Cole BF, Washko G, Jantz M, Mehta H. Tumor density is associated with response to endobronchial ultrasound-guided transbronchial needle injection of cisplatin. J Thorac Dis. 2020 Sep;12(9):4825-4832. doi: 10.21037/jtd-20-674. PMID: 33145055; PMCID: PMC7578514.
Copy Download .nbib Format: NLM
Identification of Proteins Deregulated by Platinum-Based Chemotherapy as Novel Biomarkers and Therapeutic Targets in Non-Small Cell Lung Cancer.

Frontiers in oncology

Ryan SL, Dave KA, Beard S, Gyimesi M, McTaggart M, Sahin KB, Molloy C, Gandhi NS, Boittier E, O'Leary CG, Shah ET, Bolderson E, Baird AM, Richard DJ, O'Byrne KJ, Adams MN.
PMID: 33777753
Front Oncol. 2021 Mar 11;11:615967. doi: 10.3389/fonc.2021.615967. eCollection 2021.

Platinum-based chemotherapy remains the cornerstone of treatment for most people with non-small cell lung cancer (NSCLC), either as adjuvant therapy in combination with a second cytotoxic agent or in combination with immunotherapy. Resistance to therapy, either in the form...

Cite
Ryan SL, Dave KA, Beard S, et al. Identification of Proteins Deregulated by Platinum-Based Chemotherapy as Novel Biomarkers and Therapeutic Targets in Non-Small Cell Lung Cancer. Front Oncol. 2021;11:615967doi: 10.3389/fonc.2021.615967.
Ryan, S. L., Dave, K. A., Beard, S., Gyimesi, M., McTaggart, M., Sahin, K. B., Molloy, C., Gandhi, N. S., Boittier, E., O'Leary, C. G., Shah, E. T., Bolderson, E., Baird, A. M., Richard, D. J., O'Byrne, K. J., & Adams, M. N. (2021). Identification of Proteins Deregulated by Platinum-Based Chemotherapy as Novel Biomarkers and Therapeutic Targets in Non-Small Cell Lung Cancer. Frontiers in oncology, 11615967. https://doi.org/10.3389/fonc.2021.615967
Ryan, Sarah-Louise, et al. "Identification of Proteins Deregulated by Platinum-Based Chemotherapy as Novel Biomarkers and Therapeutic Targets in Non-Small Cell Lung Cancer." Frontiers in oncology vol. 11 (2021): 615967. doi: https://doi.org/10.3389/fonc.2021.615967
Ryan SL, Dave KA, Beard S, Gyimesi M, McTaggart M, Sahin KB, Molloy C, Gandhi NS, Boittier E, O'Leary CG, Shah ET, Bolderson E, Baird AM, Richard DJ, O'Byrne KJ, Adams MN. Identification of Proteins Deregulated by Platinum-Based Chemotherapy as Novel Biomarkers and Therapeutic Targets in Non-Small Cell Lung Cancer. Front Oncol. 2021 Mar 11;11:615967. doi: 10.3389/fonc.2021.615967. eCollection 2021. PMID: 33777753; PMCID: PMC7991912.
Copy Download .nbib Format: NLM
GADD45α alleviates the CDDP resistance of SK-OV3/cddp cells via redox-mediated DNA damage.

Oncology letters

Zhang QZ, Wen F, Yang HL, Cao YY, Peng RG, Wang YM, Nie L, Qin YK, Wu JJ, Zhao X, Zi D.
PMID: 34429760
Oncol Lett. 2021 Oct;22(4):720. doi: 10.3892/ol.2021.12981. Epub 2021 Aug 10.

Epithelial ovarian cancer has the highest mortality rate of all malignant ovarian cancer types. Great progress has been made in the treatment of ovarian cancer in recent years. However, drug resistance has led to a low level of 5-year...

Cite
Zhang QZ, Wen F, Yang HL, et al. GADD45α alleviates the CDDP resistance of SK-OV3/cddp cells via redox-mediated DNA damage. Oncol Lett. 2021;22(4):720doi: 10.3892/ol.2021.12981.
Zhang, Q. Z., Wen, F., Yang, H. L., Cao, Y. Y., Peng, R. G., Wang, Y. M., Nie, L., Qin, Y. K., Wu, J. J., Zhao, X., & Zi, D. (2021). GADD45α alleviates the CDDP resistance of SK-OV3/cddp cells via redox-mediated DNA damage. Oncology letters, 22(4), 720. https://doi.org/10.3892/ol.2021.12981
Zhang, Qi-Zhu, et al. "GADD45α alleviates the CDDP resistance of SK-OV3/cddp cells via redox-mediated DNA damage." Oncology letters vol. 22,4 (2021): 720. doi: https://doi.org/10.3892/ol.2021.12981
Zhang QZ, Wen F, Yang HL, Cao YY, Peng RG, Wang YM, Nie L, Qin YK, Wu JJ, Zhao X, Zi D. GADD45α alleviates the CDDP resistance of SK-OV3/cddp cells via redox-mediated DNA damage. Oncol Lett. 2021 Oct;22(4):720. doi: 10.3892/ol.2021.12981. Epub 2021 Aug 10. PMID: 34429760; PMCID: PMC8371983.
Copy Download .nbib Format: NLM
How I treat biliary tract cancer.

ESMO open

Lamarca A, Edeline J, Goyal L.
PMID: 35032765
ESMO Open. 2022 Jan 12;7(1):100378. doi: 10.1016/j.esmoop.2021.100378. Epub 2022 Jan 12.

Management of biliary tract cancers (BTCs) is rapidly evolving. Curative management relies on surgical resection followed by adjuvant capecitabine for cholangiocarcinoma and gallbladder cancers. Unfortunately relapse rate remains high, and better adjuvant strategies are urgently required. A majority of...

Cite
Lamarca A, Edeline J, Goyal L. How I treat biliary tract cancer. ESMO Open. 2022;7(1):100378doi: 10.1016/j.esmoop.2021.100378.
Lamarca, A., Edeline, J., & Goyal, L. (2022). How I treat biliary tract cancer. ESMO open, 7(1), 100378. https://doi.org/10.1016/j.esmoop.2021.100378
Lamarca, A, et al. "How I treat biliary tract cancer." ESMO open vol. 7,1 (2022): 100378. doi: https://doi.org/10.1016/j.esmoop.2021.100378
Lamarca A, Edeline J, Goyal L. How I treat biliary tract cancer. ESMO Open. 2022 Jan 12;7(1):100378. doi: 10.1016/j.esmoop.2021.100378. Epub 2022 Jan 12. PMID: 35032765.
Copy Download .nbib Format: NLM
Cisplatin-based Electrochemotherapy Significantly Downregulates Key Heat Shock Proteins in MDA-MB-231-Human Triple-Negative Breast Cancer Cells.

Applied biochemistry and biotechnology

Sundararajan R, Giri P, Madhivanan S, Ramesh A, Kishore NK, Manjunatha M, Camarillo IG.
PMID: 34637110
Appl Biochem Biotechnol. 2022 Jan;194(1):517-528. doi: 10.1007/s12010-021-03703-9. Epub 2021 Oct 12.

Heat shock proteins (HSPs) are available and/or induced for the survival of all organisms, including eukaryotic, prokaryotic, and plants, from higher temperature stresses. They are the chaperone proteins that protect all cells against heat, as the name implies. In...

Cite
Sundararajan R, Giri P, Madhivanan S, et al. Cisplatin-based Electrochemotherapy Significantly Downregulates Key Heat Shock Proteins in MDA-MB-231-Human Triple-Negative Breast Cancer Cells. Appl Biochem Biotechnol. 2021;194(1):517-528doi: 10.1007/s12010-021-03703-9.
Sundararajan, R., Giri, P., Madhivanan, S., Ramesh, A., Kishore, N. K., Manjunatha, M., & Camarillo, I. G. (2022). Cisplatin-based Electrochemotherapy Significantly Downregulates Key Heat Shock Proteins in MDA-MB-231-Human Triple-Negative Breast Cancer Cells. Applied biochemistry and biotechnology, 194(1), 517-528. https://doi.org/10.1007/s12010-021-03703-9
Sundararajan, Raji, et al. "Cisplatin-based Electrochemotherapy Significantly Downregulates Key Heat Shock Proteins in MDA-MB-231-Human Triple-Negative Breast Cancer Cells." Applied biochemistry and biotechnology vol. 194,1 (2022): 517-528. doi: https://doi.org/10.1007/s12010-021-03703-9
Sundararajan R, Giri P, Madhivanan S, Ramesh A, Kishore NK, Manjunatha M, Camarillo IG. Cisplatin-based Electrochemotherapy Significantly Downregulates Key Heat Shock Proteins in MDA-MB-231-Human Triple-Negative Breast Cancer Cells. Appl Biochem Biotechnol. 2022 Jan;194(1):517-528. doi: 10.1007/s12010-021-03703-9. Epub 2021 Oct 12. PMID: 34637110.
Copy Download .nbib Format: NLM
Showing 8857 to 8864 of 8864 entries